Kun Ismiyatin, NIDN. 0002046001 and Adioro Soetojo, NIDN0010085102 and Soegeng Wahluyo, NIDN. 0010115405 and Indri Safitri Mukono, NIDN. 0014065303 (2017) Therapeutic Efficacy of Topical Epigallocatechin-Gallate as a New Therapeutic Strategy for Inhibition of Pain Conduction on Rat Models with Acute Pulpal Inflammation. In: Proceedings of International Medical Device and Technology Conference (iMEDiTEC 2017). Universiti Teknologi Malaysia, Johor Bahru. ISBN 978-967-0194-93-6

	Text (VALIDASI) validasi 5.pdf Download (2MB)
	Text (ARTIKEL) P30_Therapeutic-Efficacy-of-Topical-Epigallocatechin-Gallate-as-a-New-Therapeutic-Strategy-for-Inhibition-of-Pain-Conduction-on-Rat-Models-with-Acute-Pulpal-Inflammation.pdf Download (464kB)
	Text (SIMILARITY) Tunitin 5.pdf Download (3MB)

Abstract

The pulpal inflammation can lead to elicit pain in trigeminal nociceptor, produces prostaglandin (PG-E2), activating transient receptor potential vanilloid (TRPV1), causing substance P (SP) release. Here, we investigated the potential of epigallocatechin 3-gallate (EGCG) for topical medication to inhibit pain conduction in pulpal inflammation. This research on 28 male Wistar rats (Rattus norvegicus) as rat models with pulpal inflammation. Topical 0.01% or 0.1% EGCG was applied to the tooth cavity of pulpal inflammation. The treated pulp tissues were then observed using immunohistochemistry (IHC), and calculation of the amount of PG-E2, TRPV1 and SP. Results show the treatment with topical 0.1% EGCG in 24 hours pulpal inflammation showed a significant inhibit the expression of PG-E2, TRPV1, and SP compared with 0.01% EGCG, and untreated controls (P< 0.001). In conclusion, the results suggest a potential to inhibiting pain conduction of 0.1% topical EGCG in pulpal inflammation.

Actions (login required)

View Item